Detail
LncRNA Name | ANRIL |
Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
Region | GRCh38_9:21994778-22121097 Sequence |
Ensembl | ENSG00000240498 |
RefSeq | NR_003529 |
Circulating | ✘ |
Drug-resisitant | ✘ |
Prognostic | ✔ |
MiRNA | ✘ |
Variant | ✘ |
TF | ✘ |
Methylation | ✘ |
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 M8046/3 |
Methods | qPCR, RNAi, Western blot, Luciferase reporter assay etc. |
Sample | NSCLC tissues, cell lines (SK-MES-1, A549, SPC-A1, and NCI-H1975) |
Expression Pattern | up-regulated |
Function Description | The high expression level of ANRIL was positively correlated with advanced tumor-node-metastasis stage and greater tumor diameter. Furthermore, chromatin immunoprecipitation assays confirmed the physical interaction between c-Myc and ANRIL. ANRIL silencing significantly inhibited NSCLC cell proliferation. |
Pubmed ID | 27307748 |
Year | 2016 |
Title | Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. |
External Links |
Links for ANRIL | GenBank HGNC lncrnadb Noncode |
Links for non small cell lung cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.